Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Anne J Huiberts, Brechje de Gier, Christina E Hoeve, Hester E de Melker, Susan JM Hahné, Gerco den Hartog, Janneke HHM van de Wijgert, Susan van den Hof, Mirjam J Knol
|
February 16 2023
Abstract
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
